Online inquiry

IVTScrip™ mRNA-Human Aldehyde Dehydrogenase 1-A1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK15992MR)

This product GTTS-WK15992MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the Aldehyde Dehydrogenase 1-A1 protein. This product can be used in Cancer stem cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_000689.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 216
UniProt ID P00352
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human Aldehyde Dehydrogenase 1-A1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK15992MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK20775MR IVTScrip™ mRNA-Human AKR1C1, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AKR1C1
GTTS-WK28718MR IVTScrip™ mRNA-Human ASMTL, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASMTL
GTTS-WK13939MR IVTScrip™ mRNA-Human ACP2, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACP2
GTTS-WK5401MR IVTScrip™ mRNA-Human Intestinal Alkaline Phosphatase, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Intestinal Alkaline Phosphatase
GTTS-WK1163MR IVTScrip™ mRNA-Human LIN2, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LIN2
GTTS-WK27875MR IVTScrip™ mRNA-Human ATP11A, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ATP11A
GTTS-WK2399MR IVTScrip™ mRNA-Human ALDH1, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALDH1
GTTS-WK21114MR IVTScrip™ mRNA-Human ALG14, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALG14
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW